French Researchers Unload on the Covid mRNA Vaxxes! By Richard Miller (Europe)

Something of a break in the long silence from medial academics may be breaking with carefully written articles detailing the harms from the Covid vaxxes. The peer-reviewed journal, Therapies, has recently published an article: "The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: A 2-year experience report." The paper notes that in France, up until January 2023, over 155 million doses of COVID-19 vaccines were administrated, and 190,000 adverse events following immunizations (25% classified as serious) were analysed. There were 53 potential safety signals reported to the Pharmacovigilance and Risk Assessment Committee at the European Medicine Agency by the French National Agency for Medicines and Health Products Safety. Here is a list of the top 13 adverse effects:

1.Myocarditis/pericarditis (mRNA vaccines, Nuvaxovid®)

2.Heavy menstrual bleeding (mRNA vaccines)

3.Delayed reactogenicity (mRNA vaccines)

4.Erythema multiforme (mRNA vaccines)

5.Guillain-Barré syndrome (Adenovirus-based vaccines)

6.Facial paralysis (Adenovirus-based vaccines)

7.Influenza-like illness (Adenovirus-based vaccines)

8.Thrombosis with thrombocytopenia syndrome (Adenovirus-based vaccines)

9.Hypersensitivity (Adenovirus-based vaccines)

10.Capillary leak syndrome (Adenovirus-based vaccines)

11.Venous thromboembolism (Adenovirus-based vaccines)

12.Menstrual disorders (non-specific, including heavy menstrual bleeding across vaccine types)

13.Myocarditis/pericarditis (Recombinant protein-based vaccines)

This is yet another nail in the coffin of the "safe and effective" narrative.

https://petermcculloughmd.substack.com/p/france-identifies-53-covid-19-vaccine

"A new study titled, The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: A 2-year experience report, was recently published in the journal Therapies:

One of the major preventative measures developed against coronavirus disease 2019 (COVID-19) was vaccines. To monitor their use and safety of vaccines from the first utilization in humans during clinical development phases to implementation for the general population, an enhanced national pharmacovigilance system was enabled by the French National Agency for Medicines and Health Products Safety in collaboration with the 30 Regional Pharmacovigilance Centres. Here, we review the significant outcomes from a 2-year collaboration experience between the French National Agency for Medicines and Health Products Safety, the 30 Regional Pharmacovigilance Centres, disease-related experts and the pharmacovigilance and risk assessment committee at the European medicine agency. In France, until January 2023, over 155 million doses of COVID-19 vaccines were administrated, and 190,000 adverse events following immunizations (25% classified as serious) were analysed. Altogether 53 potential safety signals were reported to the Pharmacovigilance and Risk Assessment Committee at the European Medicine Agency by the French National Agency for Medicines and Health Products Safety: 13 were confirmed, 24 are still under investigation and 16 were not confirmed.

Below is the comprehensive list of safety signals identified by French pharmacovigilance authorities during their COVID-19 vaccine safety monitoring efforts:

Complete List of 53 COVID-19 Safety Signals in France Confirmed by EMA (13 Signals)

14.Myocarditis/pericarditis (mRNA vaccines, Nuvaxovid®)

15.Heavy menstrual bleeding (mRNA vaccines)

16.Delayed reactogenicity (mRNA vaccines)

17.Erythema multiforme (mRNA vaccines)

18.Guillain-Barré syndrome (Adenovirus-based vaccines)

19.Facial paralysis (Adenovirus-based vaccines)

20.Influenza-like illness (Adenovirus-based vaccines)

21.Thrombosis with thrombocytopenia syndrome (Adenovirus-based vaccines)

22.Hypersensitivity (Adenovirus-based vaccines)

23.Capillary leak syndrome (Adenovirus-based vaccines)

24.Venous thromboembolism (Adenovirus-based vaccines)

25.Menstrual disorders (non-specific, including heavy menstrual bleeding across vaccine types)

26.Myocarditis/pericarditis (Recombinant protein-based vaccines)

Under Investigation (24 Signals)

1.Parsonage-Turner syndrome

2.Acquired hemophilia

3.Autoimmune hepatitis

4.Hearing loss

5.Vasculitis

6.Autoimmune hemolytic anemia

7.Menstrual disorders (excluding heavy menstrual bleeding)

8.Systemic necrotizing vasculitis

9.Viral reactivation

10.Thromboembolic events

11.Polymyalgia rheumatica

12.Sarcoidosis

13.Rheumatoid arthritis

14.Herpes Zoster

15.Delayed neurological activation

16.Cardiovascular secondary adjusters

17.Myocarditis/pericarditis in special populations

18.Progressive neuromuscular disease

19.Vasculitis (general and advanced cases)

20.Viral reactivation (in autoimmune subgroups)

21.Autoimmune syndromes with delayed onset

22.Delayed thrombocytopenia

23.Post-vaccine fatigue syndrome

24.Hormonal disruptions (general, excluding heavy menstrual bleeding)

Not Confirmed but Under Surveillance (16 Signals - Inferred based on article, not explicitly mentioned)

1.Systemic autoimmune responses (general)

2.Hearing impacts with delayed onset

3.Cardiovascular irregularities

4.Hypersensitivity responses with mild symptoms

5.Neurological subclinical responses

6.Autoimmune hyperinflammatory conditions

7.Cyclic immune sensitivity patterns

8.Long-term joint pain and stiffness

9.Visual disturbances (mild to moderate)

10.Delayed rash or cutaneous reactions

11.Gastrointestinal irregularities

12.Sleep disturbances linked to vaccine response

13.Non-specific inflammatory reactions

14.Menstrual irregularities (non-heavy bleeding)

15.Musculoskeletal pain syndromes

16.Dermatological conditions

Even with 53 reported safety signals, this list is most definitely not reflective of all possible adverse events following COVID-19 injection. Moreover, the 25% rate of serious adverse events (totaling 42,500 cases) among reported incidents is deeply concerning. Pharmacovigilance system adverse events are often grossly underreported, meaning the true number is likely much higher. Given the massive number of reported safety signals and serious adverse event reports, why did global public health authorities continue to endorse widespread administration of these novel injectable products? The worldwide market withdrawal of COVID-19 'vaccines' and accountability for this public health disaster are LONG overdue."